Tonix Pharmaceuticals Files 8-K
Ticker: TNXP · Form: 8-K · Filed: Apr 1, 2025 · CIK: 1430306
Sentiment: neutral
Topics: 8-K, corporate-filing, financial-reporting
Related Tickers: TNXP
TL;DR
TONX filed an 8-K on April 1st, check it for updates.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on April 1, 2025, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, incorporated in Nevada, has its principal executive offices in Chatham, New Jersey.
Why It Matters
This filing provides an update on Tonix Pharmaceuticals' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports on corporate events and financial statements without immediate, significant market-moving news.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- April 1, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of Incorporation
- Chatham, New Jersey (location) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report for Tonix Pharmaceuticals Holding Corp., covering items such as Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on April 1, 2025.
In which state is Tonix Pharmaceuticals Holding Corp. incorporated?
Tonix Pharmaceuticals Holding Corp. is incorporated in Nevada.
What is the company's principal executive office address?
The company's principal executive offices are located at 26 Main Street, Chatham, New Jersey, 07928.
What was the former name of Tonix Pharmaceuticals Holding Corp.?
The former name of Tonix Pharmaceuticals Holding Corp. was TAMANDARE EXPLORATIONS INC., with a date of name change on March 20, 2008.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 1, 2025 regarding Tonix Pharmaceuticals Holding Corp. (TNXP).